US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Nasus Pharma Ltd.

3.69

+0.12003.36%

Post-market: 3.750.0600+1.63%19:55 EDT

Volume:57.26K

Turnover:215.16K

Market Cap:43.39M

PE:-3.45

High:4.00

Open:4.00

Low:3.60

Close:3.57

52wk High:9.50

52wk Low:1.98

Shares:11.76M

Float Shares:6.21M

Volume Ratio:1.48

T/O Rate:0.92%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-1.0691

EPS(LYR):-0.7311

ROE:-316.04%

ROA:-96.73%

PB:3.95

PE(LYR):-5.05

Loading ...

Overview Company News Filings

Nasus Pharma Announces Enrollment and Dosing of First Patient in Phase 1 Study of Ns003 Intranasal Formulation of Ondansetron

THOMSON REUTERS

Nasus Pharma Announces Enrollment and Dosing of First Patient in Phase 1 Study of NS003 Intranasal Formulation of Ondansetron

Nasus Pharma Files Form 3 for Interim CFO Oren Elmaliah

Nasus Pharma : Enters Atm Sales Agreement with Btig for up to $8.50m in Ordinary Shares -SEC Filing

THOMSON REUTERS

Nasus Pharma Sets Up $8.5 Million At-the-Market Equity Program to Fund Clinical Pipeline

Nasus Pharma Ltd: Enters At-the-Market Sales Agreement with Btig to Offer Ordinary Shares

THOMSON REUTERS

Nasus Pharma : to Use Proceeds for Ns002 Clinical Development, Pipeline Studies, Working Capital

THOMSON REUTERS

Nasus Pharma Wins FDA Clearance to Begin NS002 Anaphylaxis Trial

Nasus Pharma - Pivotal Study Planned for Q4 2026; Topline Data Readout Anticipated Q1 2027

THOMSON REUTERS

Nasus Pharma Announces FDA Clearance to Initiate Clinical Study of Ns002 in the Treatment of Anaphylaxis

THOMSON REUTERS

Nasus Pharma Announces FDA Clearance to Initiate Clinical Study of NS002 in the Treatment of Anaphylaxis

Amex Halt Add Info Lst 3.470000

THOMSON REUTERS

Nasus Pharma to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

Nasus Pharma Sets October 8, 2026 Shareholder Meeting to Vote on Governance, Executive Pay and Option Pool

Nasus Pharma Announces Annual, Special Shareholder Meeting

Nasus Pharma Files $50 Million Shelf Registration

MT Newswires Live

Nasus Pharma files $50M ordinary shares offering

Nasus Pharma - May Offer up to $50 Mln of Ordinary Shares - SEC Filing

THOMSON REUTERS

Amex Halt Add Info Lst 3.500000

THOMSON REUTERS

Nasus Pharma Names Interim CFO as Longtime Finance Chief Resigns

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg1.tigeractivity.com/stock/NSRX/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NSRX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NSRX\",,,,,undefined,":{"symbol":"NSRX","market":"US","secType":"STK","nameCN":"Nasus Pharma Ltd.","latestPrice":3.69,"timestamp":1790798400000,"preClose":3.57,"halted":0,"volume":57257,"hourTrading":{"tag":"盘后","latestPrice":3.75,"preClose":3.69,"latestTime":"19:55 EDT","volume":1033,"amount":3793.98,"timestamp":1790812542176,"change":0.06,"changeRate":0.01626,"amplitude":0.03794},"delay":0,"changeRate":0.033613445378151294,"floatShares":6214000,"shares":11758900,"eps":-1.06915,"marketStatus":"Not Yet Opened","change":0.12,"latestTime":"09-30 16:00:00 EDT","open":4,"high":4,"low":3.6,"amount":215159.1579287,"amplitude":0.112045,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.06915,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1790841600000},"marketStatusCode":0,"adr":0,"listingDate":1755057600000,"exchange":"AMEX","adjPreClose":3.57,"preHourTrading":{"tag":"盘前","latestPrice":4,"preClose":3.57,"latestTime":"09:12 EDT","volume":1374,"amount":5451.5211468,"timestamp":1790773937321,"change":0.43,"changeRate":0.120448,"amplitude":0.039804},"postHourTrading":{"tag":"盘后","latestPrice":3.75,"preClose":3.69,"latestTime":"19:55 EDT","volume":1033,"amount":3793.98,"timestamp":1790812542176,"change":0.06,"changeRate":0.01626,"amplitude":0.03794},"volumeRatio":1.484634},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NSRX\",,,,,undefined,":{"symbol":"NSRX","floatShares":6214000,"roa":"-96.73%","roe":"-316.04%","lyrEps":-0.731074,"volumeRatio":1.484634,"shares":11758900,"dividePrice":0,"high":4,"amplitude":0.112045,"preClose":3.57,"low":3.6,"week52Low":1.98,"pbRate":"3.95","week52High":9.5,"institutionHeld":0,"latestPrice":3.69,"eps":-1.06915,"divideRate":0,"volume":57257,"delay":0,"ttmEps":-1.06915,"open":4,"prevYearClose":9.15,"prevWeekClose":3.48,"prevMonthClose":4.084,"prevQuarterClose":3.5,"fiveDayClose":3.64,"twentyDayClose":3.825,"sixtyDayClose":3.05},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NSRX\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NSRX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NSRX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":2,"updateTime":1766116800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/NSRX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"NSRX","date":"2026-09-29","current":-3.45134,"percent":0.960854,"low":-51.389177,"twenty":-44.402851,"median":-26.264888,"eighty":-5.759414,"high":-3.720961,"avg":-23.743982,"sd":17.784692,"marketCap":42052570},"quantilePoints":[{"date":"2025-08-15","current":-47.343663,"twenty":-48.284655,"median":-47.931783,"eighty":-47.578911,"marketCap":72530491},{"date":"2025-08-22","current":-50.265593,"twenty":-50.691372,"median":-49.082873,"eighty":-48.024103,"marketCap":77006889},{"date":"2025-08-29","current":-47.604473,"twenty":-50.029049,"median":-48.047994,"eighty":-47.509856,"marketCap":72930053},{"date":"2025-09-05","current":-47.370886,"twenty":-49.082873,"median":-47.841017,"eighty":-47.486202,"marketCap":72572198},{"date":"2025-09-12","current":-48.136697,"twenty":-48.519903,"median":-47.66361,"eighty":-47.343663,"marketCap":73745420},{"date":"2025-09-19","current":-47.384488,"twenty":-48.195834,"median":-47.722745,"eighty":-47.36793,"marketCap":72593035},{"date":"2025-09-26","current":-47.604473,"twenty":-48.136697,"median":-47.604473,"eighty":-47.343663,"marketCap":72930053},{"date":"2025-10-03","current":-36.900859,"twenty":-48.077561,"median":-47.51577,"eighty":-47.308794,"marketCap":56532116},{"date":"2025-10-10","current":-45.830394,"twenty":-48.047993,"median":-47.384488,"eighty":-45.830394,"marketCap":70212163},{"date":"2025-10-17","current":-46.835706,"twenty":-47.900153,"median":-47.36793,"eighty":-45.534713,"marketCap":71752301},{"date":"2025-10-24","current":-44.943354,"twenty":-47.900153,"median":-47.314116,"eighty":-44.943354,"marketCap":68853218},{"date":"2025-10-31","current":-46.007802,"twenty":-47.900153,"median":-47.308794,"eighty":-45.239034,"marketCap":70483952},{"date":"2025-11-07","current":-44.647674,"twenty":-47.781881,"median":-47.308794,"eighty":-44.943354,"marketCap":68400236},{"date":"2025-11-14","current":-46.717433,"twenty":-47.722745,"median":-47.22009,"eighty":-44.647674,"marketCap":71571108},{"date":"2025-11-21","current":-41.395195,"twenty":-47.722745,"median":-46.835706,"eighty":-44.351994,"marketCap":63417438},{"date":"2025-11-28","current":-41.395195,"twenty":-47.675437,"median":-46.717433,"eighty":-43.654189,"marketCap":63417438},{"date":"2025-12-05","current":-40.508154,"twenty":-47.6163,"median":-46.155642,"eighty":-42.826285,"marketCap":62058492},{"date":"2025-12-12","current":-38.438395,"twenty":-47.604473,"median":-45.830394,"eighty":-41.395195,"marketCap":58887621},{"date":"2025-12-19","current":-37.669627,"twenty":-47.557164,"median":-45.682553,"eighty":-41.383368,"marketCap":57709868},{"date":"2025-12-26","current":-44.351994,"twenty":-47.509856,"median":-45.298465,"eighty":-41.395195,"marketCap":67947255},{"date":"2026-01-02","current":-43.332802,"twenty":-47.445516,"median":-44.987706,"eighty":-41.359713,"marketCap":82895651},{"date":"2026-01-09","current":-33.62436,"twenty":-47.384488,"median":-44.884218,"eighty":-40.236129,"marketCap":64323401},{"date":"2026-01-16","current":-33.62436,"twenty":-47.379047,"median":-44.647674,"eighty":-40.035066,"marketCap":64323401},{"date":"2026-01-23","current":-31.392839,"twenty":-47.370295,"median":-44.529402,"eighty":-38.570149,"marketCap":60054501},{"date":"2026-01-30","current":-26.473264,"twenty":-47.36793,"median":-44.351994,"eighty":-37.823381,"marketCap":50643354},{"date":"2026-02-06","current":-27.467787,"twenty":-47.363077,"median":-44.351994,"eighty":-35.774424,"marketCap":52545877},{"date":"2026-02-13","current":-34.411045,"twenty":-47.337754,"median":-43.81977,"eighty":-34.753161,"marketCap":65828330},{"date":"2026-02-20","current":-30.724148,"twenty":-47.314116,"median":-43.332802,"eighty":-34.411045,"marketCap":58775295},{"date":"2026-02-27","current":-31.33863,"twenty":-47.308794,"median":-42.873594,"eighty":-33.62436,"marketCap":59950800},{"date":"2026-03-06","current":-30.662699,"twenty":-47.308794,"median":-41.857638,"eighty":-33.151251,"marketCap":58657744},{"date":"2026-03-13","current":-28.389112,"twenty":-47.308794,"median":-41.483899,"eighty":-32.108896,"marketCap":54308372},{"date":"2026-03-20","current":-15.239177,"twenty":-47.308794,"median":-41.395195,"eighty":-31.096524,"marketCap":29152546},{"date":"2026-03-27","current":-4.817647,"twenty":-47.249657,"median":-41.365627,"eighty":-30.724148,"marketCap":28212141},{"date":"2026-04-02","current":-5.099481,"twenty":-47.249657,"median":-40.41945,"eighty":-29.587069,"marketCap":29862560},{"date":"2026-04-10","current":-4.639528,"twenty":-47.202349,"median":-40.212475,"eighty":-29.052754,"marketCap":27169074},{"date":"2026-04-17","current":-4.499542,"twenty":-47.048596,"median":-40.212475,"eighty":-28.102929,"marketCap":26349318},{"date":"2026-04-24","current":-6.799308,"twenty":-46.871188,"median":-39.325435,"eighty":-27.041563,"marketCap":39816747},{"date":"2026-05-01","current":-5.39945,"twenty":-46.741088,"median":-38.438986,"eighty":-25.76289,"marketCap":31619181},{"date":"2026-05-08","current":-6.77931,"twenty":-46.717433,"median":-38.438395,"eighty":-18.667992,"marketCap":39699639},{"date":"2026-05-15","current":-5.939395,"twenty":-46.670125,"median":-36.896469,"eighty":-15.349784,"marketCap":34781099},{"date":"2026-05-22","current":-5.739416,"twenty":-46.374445,"median":-36.254495,"eighty":-7.119275,"marketCap":33610018},{"date":"2026-05-29","current":-6.399349,"twenty":-46.126074,"median":-35.850198,"eighty":-6.399349,"marketCap":37474585},{"date":"2026-06-05","current":-6.47934,"twenty":-46.007802,"median":-35.518691,"eighty":-6.399349,"marketCap":37943017},{"date":"2026-06-12","current":-6.339355,"twenty":-45.901357,"median":-34.571052,"eighty":-6.29136,"marketCap":37123261},{"date":"2026-06-18","current":-6.159373,"twenty":-45.830394,"median":-34.411045,"eighty":-6.175371,"marketCap":36069288},{"date":"2026-06-26","current":-6.599328,"twenty":-45.830394,"median":-33.62436,"eighty":-6.175371,"marketCap":38645666},{"date":"2026-07-02","current":-7.029284,"twenty":-45.771258,"median":-33.505965,"eighty":-6.207368,"marketCap":41163490},{"date":"2026-07-10","current":-6.019387,"twenty":-45.49935,"median":-32.81339,"eighty":-6.167372,"marketCap":35249532},{"date":"2026-07-17","current":-6.139375,"twenty":-45.334124,"median":-32.21535,"eighty":-6.139375,"marketCap":35952180},{"date":"2026-07-24","current":-6.18537,"twenty":-45.191725,"median":-31.392839,"eighty":-6.099379,"marketCap":36221529},{"date":"2026-07-31","current":-6.359353,"twenty":-45.00249,"median":-31.096524,"eighty":-6.099379,"marketCap":37240369},{"date":"2026-08-07","current":-6.77931,"twenty":-44.972922,"median":-30.724148,"eighty":-6.099379,"marketCap":39699639},{"date":"2026-08-14","current":-6.399349,"twenty":-44.943354,"median":-30.662699,"eighty":-6.099379,"marketCap":37474585},{"date":"2026-08-21","current":-4.275233,"twenty":-44.884218,"median":-29.56931,"eighty":-6.079381,"marketCap":45086610},{"date":"2026-08-28","current":-4.552846,"twenty":-44.798471,"median":-29.220042,"eighty":-6.059383,"marketCap":48014312},{"date":"2026-09-04","current":-4.164188,"twenty":-44.647674,"median":-28.450561,"eighty":-6.019387,"marketCap":43915530},{"date":"2026-09-11","current":-3.720961,"twenty":-44.647674,"median":-28.266216,"eighty":-5.923397,"marketCap":39241256},{"date":"2026-09-18","current":-3.920893,"twenty":-44.647674,"median":-27.467787,"eighty":-5.819408,"marketCap":41349742},{"date":"2026-09-25","current":-3.865357,"twenty":-44.458439,"median":-26.828451,"eighty":-5.775412,"marketCap":40764051},{"date":"2026-09-29","current":-3.987537,"twenty":-44.402851,"median":-26.264888,"eighty":-5.759414,"marketCap":42052570}],"updateTime":1790814177646},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NSRX\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2671113562","title":"Nasus Pharma Announces Enrollment and Dosing of First Patient in Phase 1 Study of Ns003 Intranasal Formulation of Ondansetron","url":"https://stock-news.laohu8.com/highlight/detail?id=2671113562","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671113562?lang=en_us&edition=fundamental","pubTime":"2026-09-29 20:00","pubTimestamp":1790683207,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260929:nTUA46JDLL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","NSRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671211934","title":"Nasus Pharma Announces Enrollment and Dosing of First Patient in Phase 1 Study of NS003 Intranasal Formulation of Ondansetron","url":"https://stock-news.laohu8.com/highlight/detail?id=2671211934","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671211934?lang=en_us&edition=fundamental","pubTime":"2026-09-29 20:00","pubTimestamp":1790683200,"startTime":"0","endTime":"0","summary":"Topline Data from First-in-Human Pharmacokinetic Study Anticipated in the Fourth Quarter of 2026TEL AVIV, Israel, Sept.  29, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd.(NYSE: NSRX) (“Nasus Pharma” or t","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/29/3370749/0/en/nasus-pharma-announces-enrollment-and-dosing-of-first-patient-in-phase-1-study-of-ns003-intranasal-formulation-of-ondansetron.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4181","BK4123","AUC","BK4218","CINV","PK","KBWY","BK4007","NSRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669910784","title":"Nasus Pharma Files Form 3 for Interim CFO Oren Elmaliah","url":"https://stock-news.laohu8.com/highlight/detail?id=2669910784","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669910784?lang=en_us&edition=fundamental","pubTime":"2026-09-23 18:15","pubTimestamp":1790158520,"startTime":"0","endTime":"0","summary":"Nasus Pharma files Form 3 for Interim CFO Oren ElmaliahNasus Pharma interim CFO Oren Elmaliah filed an initial ownership report listing options for 52,140 ordinary shares exercisable at USD 1.23-6.05.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260923:nNDL5JQP12:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NSRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668730829","title":"Nasus Pharma : Enters Atm Sales Agreement with Btig for up to $8.50m in Ordinary Shares -SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2668730829","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668730829?lang=en_us&edition=fundamental","pubTime":"2026-09-19 04:55","pubTimestamp":1789764958,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260918:nFWN45A0P1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","NSRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668973006","title":"Nasus Pharma Sets Up $8.5 Million At-the-Market Equity Program to Fund Clinical Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2668973006","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668973006?lang=en_us&edition=fundamental","pubTime":"2026-09-19 04:42","pubTimestamp":1789764165,"startTime":"0","endTime":"0","summary":"An update from Nasus Pharma Ltd. ( ($NSRX) ) is now available. On September 18, 2026, Nasus Pharma Ltd. entered into an at-the-market sales agreeme...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/nasus-pharma-sets-up-8-5-million-at-the-market-equity-program-to-fund-clinical-pipeline?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/nasus-pharma-sets-up-8-5-million-at-the-market-equity-program-to-fund-clinical-pipeline?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4215","REZ","EQR","BK4007","NSRX","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668973885","title":"Nasus Pharma Ltd: Enters At-the-Market Sales Agreement with Btig to Offer Ordinary Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2668973885","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668973885?lang=en_us&edition=fundamental","pubTime":"2026-09-19 04:09","pubTimestamp":1789762197,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260918:nFWN45A0JY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NSRX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668973832","title":"Nasus Pharma : to Use Proceeds for Ns002 Clinical Development, Pipeline Studies, Working Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2668973832","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668973832?lang=en_us&edition=fundamental","pubTime":"2026-09-19 04:09","pubTimestamp":1789762197,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260918:nFWN45A0JY:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","NSRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667698696","title":"Nasus Pharma Wins FDA Clearance to Begin NS002 Anaphylaxis Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2667698696","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667698696?lang=en_us&edition=fundamental","pubTime":"2026-09-14 20:47","pubTimestamp":1789390067,"startTime":"0","endTime":"0","summary":"Nasus Pharma Ltd. ( ($NSRX) ) has shared an announcement. On September 14, 2026, Nasus Pharma announced that the U.S. Food and Drug Administration ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/nasus-pharma-wins-fda-clearance-to-begin-ns002-anaphylaxis-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/nasus-pharma-wins-fda-clearance-to-begin-ns002-anaphylaxis-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BK4007","LABU","NSRX","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667665937","title":"Nasus Pharma - Pivotal Study Planned for Q4 2026; Topline Data Readout Anticipated Q1 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2667665937","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667665937?lang=en_us&edition=fundamental","pubTime":"2026-09-14 20:00","pubTimestamp":1789387200,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260914:nTUA9BKDGC:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","NSRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667663014","title":"Nasus Pharma Announces FDA Clearance to Initiate Clinical Study of Ns002 in the Treatment of Anaphylaxis","url":"https://stock-news.laohu8.com/highlight/detail?id=2667663014","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667663014?lang=en_us&edition=fundamental","pubTime":"2026-09-14 20:00","pubTimestamp":1789387200,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260914:nTUA9BKDGC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","NSRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667665532","title":"Nasus Pharma Announces FDA Clearance to Initiate Clinical Study of NS002 in the Treatment of Anaphylaxis","url":"https://stock-news.laohu8.com/highlight/detail?id=2667665532","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667665532?lang=en_us&edition=fundamental","pubTime":"2026-09-14 20:00","pubTimestamp":1789387200,"startTime":"0","endTime":"0","summary":"Clinical study to evaluate NS002, the Company's investigational intranasal epinephrine powder, as a needle-free alternative to EpiPen for patients experiencing anaphylaxis and will compare self-admini","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/14/3361032/0/en/nasus-pharma-announces-fda-clearance-to-initiate-clinical-study-of-ns002-in-the-treatment-of-anaphylaxis.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NSRX","BK4588","LABU","BK4007","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666539006","title":"Amex Halt Add Info Lst 3.470000","url":"https://stock-news.laohu8.com/highlight/detail?id=2666539006","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666539006?lang=en_us&edition=fundamental","pubTime":"2026-09-09 23:11","pubTimestamp":1788966660,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nAQN2MIKGV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","NSRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665781403","title":"Nasus Pharma to Participate in the H.C. Wainwright 28th Annual Global Investment Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2665781403","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665781403?lang=en_us&edition=fundamental","pubTime":"2026-09-08 19:30","pubTimestamp":1788867000,"startTime":"0","endTime":"0","summary":"TEL AVIV, Israel, Sept.  08, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) (\"Nasus\", “Nasus Pharma” or the \"Company\"), a clinical-stage pharmaceutical company focused on the development of i","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/08/3357529/0/en/nasus-pharma-to-participate-in-the-h-c-wainwright-28th-annual-global-investment-conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NSRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665351615","title":"Nasus Pharma Sets October 8, 2026 Shareholder Meeting to Vote on Governance, Executive Pay and Option Pool","url":"https://stock-news.laohu8.com/highlight/detail?id=2665351615","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665351615?lang=en_us&edition=fundamental","pubTime":"2026-09-05 04:28","pubTimestamp":1788553680,"startTime":"0","endTime":"0","summary":"The latest update is out from Nasus Pharma Ltd. ( ($NSRX) ). Nasus Pharma Ltd. has called an Annual and Special General Meeting of shareholders for...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/nasus-pharma-sets-october-8-2026-shareholder-meeting-to-vote-on-governance-executive-pay-and-option-pool?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/nasus-pharma-sets-october-8-2026-shareholder-meeting-to-vote-on-governance-executive-pay-and-option-pool?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NSRX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665359233","title":"Nasus Pharma Announces Annual, Special Shareholder Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2665359233","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665359233?lang=en_us&edition=fundamental","pubTime":"2026-09-05 04:06","pubTimestamp":1788552384,"startTime":"0","endTime":"0","summary":"Nasus Pharma announces annual, special shareholder meetingNasus Pharma will hold its annual and special general meeting of shareholders in Tel Aviv, Israel on Oct. 8, 2026.Votes will cover reappointin","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260904:nNDL6BzZj4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NSRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664275861","title":"Nasus Pharma Files $50 Million Shelf Registration","url":"https://stock-news.laohu8.com/highlight/detail?id=2664275861","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664275861?lang=en_us&edition=fundamental","pubTime":"2026-09-02 05:56","pubTimestamp":1788299811,"startTime":"0","endTime":"0","summary":"Nasus Pharma (NSRX) on Tuesday filed a prospectus to offer up to $50 million of ordinary shares from time to time in one or more offerings, with pricing and terms to be set in future supplements.The company plans to use the net proceeds for working capital and general corporate purposes.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","NSRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664861386","title":"Nasus Pharma files $50M ordinary shares offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2664861386","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664861386?lang=en_us&edition=fundamental","pubTime":"2026-09-02 04:55","pubTimestamp":1788296108,"startTime":"0","endTime":"0","summary":"16:52 EDT Nasus Pharma (NSRX) files $50M ordinary shares offering Published first on TheFly – the ultimate source for real-time, market-moving brea...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/nasus-pharma-files-50m-ordinary-shares-offering-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/nasus-pharma-files-50m-ordinary-shares-offering-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","NSRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664886909","title":"Nasus Pharma - May Offer up to $50 Mln of Ordinary Shares - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2664886909","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664886909?lang=en_us&edition=fundamental","pubTime":"2026-09-02 04:51","pubTimestamp":1788295912,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260901:nFWN44T0M3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","NSRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664868515","title":"Amex Halt Add Info Lst 3.500000","url":"https://stock-news.laohu8.com/highlight/detail?id=2664868515","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664868515?lang=en_us&edition=fundamental","pubTime":"2026-09-02 00:15","pubTimestamp":1788279309,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260901:nAQN2MHJNP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NSRX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660426740","title":"Nasus Pharma Names Interim CFO as Longtime Finance Chief Resigns","url":"https://stock-news.laohu8.com/highlight/detail?id=2660426740","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660426740?lang=en_us&edition=fundamental","pubTime":"2026-08-19 21:47","pubTimestamp":1787147264,"startTime":"0","endTime":"0","summary":"Nasus Pharma Ltd. ( ($NSRX) ) has provided an update. Nasus Pharma Ltd. reported on August 19, 2026, that Chief Financial Officer Eyal Rubin has re...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/nasus-pharma-names-interim-cfo-as-longtime-finance-chief-resigns?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/nasus-pharma-names-interim-cfo-as-longtime-finance-chief-resigns?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","NSRX"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":40,"code":"91000000","status":"200"}]}}